MREO - Mereo Bio reports positive results from Phase 1b/2 alvelestat study in COVID-19 respiratory disease

Mereo BioPharma (NASDAQ:MREO) perks up 1.8% premarket after announcing top-line data from a Phase 1b/2 COSTA clinical trial evaluating alvelestat in hospitalized COVID-19 Respiratory Disease patients. Enrolled subjects received alvelestat or matched placebo, twice daily, for 5 days, with optional extension to 10 days per investigator judgement. Primary Endpoint: Safety and Tolerability to Day 60 Consistent with the known safety profile of alvelestat, no safety signals were observed in lab safety monitoring, including none in liver, renal and vital sign parameters. There were no deaths on study. Secondary Efficacy Endpoints: Clinical Outcome Measures: In the alvelestat arm 62.5% (5/8) patients had a 2-point decrease in the WHO Disease Severity score by Day 5, compared to 28.5% (2/7) in the placebo arm. At Day 7 this improvement increased to 87.5% (7/8) in the alvelestat arm and 57% (4/7) in the placebo arm. Inflammatory Biomarkers: The pro-inflammatory blood biomarker, Interleukin-6 was elevated in this population and decreased

For further details see:

Mereo Bio reports positive results from Phase 1b/2 alvelestat study in COVID-19 respiratory disease